Basiliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD25 |
| Names | |
| Trade names | Simulect |
| Clinical data | |
| Main uses | Kidney transplant[1] |
| Side effects | Constipation, nausea, abdominal pain,heart burn,high potassium,low potassium, headache, swelling, fever, shortness of breath, trouble sleeping[1] |
| Pregnancy category | |
| External links | |
| AHFS/Drugs.com | Monograph |
| Legal | |
| License data | |
| Pharmacokinetics | |
| Eliminationhalf-life | 7.2 days |
| Chemical and physical data | |
| Formula | C6378H9844N1698O1997S48 |
| Molar mass | 143801.68 g·mol−1 |
Basiliximab, sold under the brand nameSimulect, is a medication used to preventrejection following akidney transplant.[1] It is used together withciclosporin andcorticosteroids.[2] It is given by injection into a vein.[2]
Common side effects include constipation, nausea, abdominal pain,heart burn,high potassium,low potassium, headache, swelling, fever, shortness of breath, and trouble sleeping.[1] Other side effects may include infections andanaphylaxis.[1] Use in pregnancy is not recommended.[2] It is amonoclonal antibody that attaches toCD25 onT cells and thus blocksinterleukin-2.[3]
Basiliximab was approved for medical use in the United States and Europe in 1998.[1][3] In the United Kingdom a typical dose costs about £840 as of 2021.[2] In the United States this amount costs about 4,100 USD.[4]
Medical uses
Basiliximab is animmunosuppressant agent used to prevent immediatetransplant rejection in people who are receiving kidney transplants, in combination with other agents.[5] It has been reported that some cases oflichen planus have been successfully treated with basiliximab as an alternative therapy tocyclosporin. No short-term side effects have been reported.[6]
Dosage
It is given as a dose of 20 mg within two hours of surgery followed by 20 mg 4 days later.[2]
Mechanism of action
Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production ofantibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[7][8]
Chemistry
It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[7][8]
History
It is aNovartis product and was approved by theFood and Drug Administration (FDA) in 1998.[9]
See also
References
- ↑1.01.11.21.31.41.5"Basiliximab Monograph for Professionals".Drugs.com.Archived from the original on 26 August 2019. Retrieved8 January 2022.
- ↑2.02.12.22.32.4BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 891.ISBN 978-0857114105.
- ↑3.03.1"Simulect".Archived from the original on 11 January 2022. Retrieved8 January 2022.
- ↑"Simulect Prices, Coupons & Patient Assistance Programs".Drugs.com.Archived from the original on 24 January 2021. Retrieved8 January 2022.
- ↑MedlinePlus. Last Revised - June 15, 2012Basiliximab InjectionArchived 2016-07-05 at theWayback Machine
- ↑Katsambas AD, Lotti TM (2003).European handbook of dermatological treatments (2nd ed.). p. 291.ISBN 3-540-00878-0.
- ↑7.07.1Hardinger KL, Brennan DC, Klein CL (July 2013). "Selection of induction therapy in kidney transplantation".Transplant International.26 (7): 662–72.doi:10.1111/tri.12043.PMID 23279211.S2CID 3296555.
- ↑8.08.1"Basiliximab label"(PDF).Archived(PDF) from the original on 2017-02-22. Retrieved2021-02-04.
- ↑Waldmann TA (March 2003)."Immunotherapy: past, present and future".Nature Medicine.9 (3): 269–77.doi:10.1038/nm0303-269.PMID 12612576.S2CID 9745527.Archived from the original on 2021-04-13. Retrieved2021-02-04.
External links
| Identifiers: |
|
|---|
- Pages using duplicate arguments in template calls
- Webarchive template wayback links
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Drug has EMA link
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles with changed EBI identifier
- Immunosuppressants
- Novartis brands
- RTT